The aim of the study was to identify vitamin D accumulation properties in hospitalized COVID-19 patients, while also identifying changes in inflammatory markers for subjects taking vitamin D and the placebo group.
Protocol number of study: 2021sunD3 SARS-CoV-2
Start of study: 1 February 2021
End of study:13 June 2021
Location of the study:Pauls Stradiņš Clinical University Hospital, Riga, Latvia
Head researcher: Prof. Valdis Pīrāgs
Inclusion criteria: hospitalized patients aged ≥ 18 with a positive SARS – CoV – 2 RNS test, vitamin D blood levels of < 30 ng/ml, voluntary consent by the subject to participate in the study
The subjects were divided into 2 groups:
• Treatment group: COVID-19 patients whose vitamin D level was < 30 ng/ml and who took the assayable spray form of vitamin D sublingually 4,000IU/3x/d after a meal in the morning, midday and evening, shaking the product well prior to use.
• Control group: COVID-19 patients whose vitamin D level was < 30 ng/ml and who took a placebo sublingually 3x/d after a meal in the morning, midday and evening, shaking the product well prior to use.
Overall, the study analyzed 300 hospitalized COVID-19 patients who had been hospitalized with mild to severe illness. Based on exclusion criteria, 100 patients qualified for the study. All patients were randomly divided into two groups. The first group (treatment group) was given vitamin D3 (cholecalciferol) in spray form, while the other (control group) was given a placebo spray. The first group consisted of 48 patients, the control group consisted of 52 patients.
Image 1. Changes in patients’ C-reactive protein (CRP) depending on treatment
• Vitamin D in spray form is an optional preparation for rapidly eliminating a vitamin D deficiency in hospitalized patients of the COVID-19 pneumonia and other acute inflammatory disease.
• Vitamin D in spray form effectively reduces the level of inflammatory marker CRP in patients of the COVID-19 pneumonia, especially when combined with dexamethasone (see Image 1).